NASDAQ$ATYR
aTyr Pharma Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open
Briefing
aTyr Pharma Inc reported no revenue and a net loss of $19.5 million for Q2 2025.
aTyr Pharma Inc, a clinical-stage biotechnology company, reported financial results for the second quarter ended June 30, 2025. The company recorded zero revenue from license and collaboration agreements and a net loss attributable to common stockholders of $19.5 million, or $0.22 per share. Cash, cash equivalents and available-for-sale investments totaled $80.3 million at quarter end, supporting ongoing development of efzofitimod.
- Q2 2025 revenue was zero as the company remains pre-commercial with no product sales.
- Net loss widened to $19.5 million compared to $16.3 million in Q2 2024, driven by higher R&D and G&A expenses.
- Cash position strengthened to $80.3 million after raising $36.7 million via ATM equity offerings in the first half of 2025.
- Topline data from the Phase 3 EFZO-FIT study in pulmonary sarcoidosis expected in mid-September 2025.
Headline financials
Revenue & EPS history
aTyr Pharma Inc · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
-2.0%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+10.0%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+7.4%
Q2 2020
Best reaction
-8.6%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q4 2025 | -8.6% | +2.2% | -6.1% | |
| Q3 2025 | -5.4% | -3.3% | +1.2% | |
| Q1 2025 | -2.2% | +0.3% | +66.6% | |
| Q3 2024 | -4.6% | +7.4% | +3.4% | |
| Q2 2024 | -3.9% | +5.5% | +3.3% | |
| Q1 2024 | +0.6% | +6.9% | +8.8% | |
| Q3 2023 | -5.7% | -9.0% | -1.6% | |
| Q4 2022 | +1.0% | -3.6% | -1.0% | |
| Q4 2021 | +0.0% | +6.5% | +4.2% | |
| Q3 2021 | +1.2% | -1.7% | -7.0% | |
| Q2 2021 | +0.8% | -2.3% | +14.2% | |
| Q1 2021 | +1.7% | +11.6% | +31.2% | |
| Q3 2020 | +0.6% | -1.8% | +38.1% | |
| Q2 2020 | +7.4% | +20.6% | -1.4% | |
| Q1 2020 | -5.4% | -6.1% | -15.9% | |
| Q3 2019 | -6.2% | -3.9% | +7.2% | |
| Q2 2019 | -5.7% | +4.7% | +24.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro